U.S. IDE Enrollment follows groundbreaking 96% procedural success at 12 months in European feasibility study Pulse Biosciences, Inc. (Nasdaq: PLSE), developer of nPulse technology using proprietary ...
A procedure that treats abnormal heart rhythms by using heat energy to destroy the faulty electrical pathways in the heart. In a remarkable clinical achievement, Kauvery Hospital, Alwarpet, ...
U.S. IDE Enrollment follows groundbreaking 96% procedural success at 12 months in European feasibility studyHAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), developer of ...
Pulse Biosciences (PLSE) highlights promising AFib catheter data and IDE-cleared pivotal trial progress—plus thyroid ...
Pulse Biosciences is keeping the noise level up by announcing the enrollment of the first patients in the NANOPULSE-AF study, a prospective, multicenter, IDE pivotal clinical investigation currently ...
From its first use in 1998, to its status as a routine management strategy when medication is not an option, our understanding of catheter ablation for AF has grown immensely 4. Over the past 28 years ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results